<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>APPROVED</status><version>v2</version><patient-age>61</patient-age><report-id>PHEH2012US005409</report-id><gender>female</gender><reactions><reaction>Aching muscles</reaction><reaction>Flu-like symptoms</reaction><reaction>Nausea</reaction><reaction>Diarrhea</reaction><reaction>Vomiting</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>TASIGNA</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>HYDROCODONE W/APAP</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>LORAZEPAM</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>CENESTIN</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>PROPRANOLOL</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>PHENYTOIN</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Chronic myeloid leukaemia</indication></indications><outcomes/><country>United States</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4053136_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20121211133934</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>2</safetyreportversion>
		<safetyreportid>PHEH2012US005409</safetyreportid>
		<primarysourcecountry>US</primarysourcecountry>
		<occurcountry>US</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2012-12-11</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="2">No</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2012-03-08</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2012-12-05</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHEH2012US005409</companynumb>
		<medicallyconfirm>2</medicallyconfirm>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>US</reportercountry>
			<qualification code="5">Consumer or non-health professional</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>US</reportercountry>
			<qualification code="1">Physician</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>US</reportercountry>
			<qualification code="5">Consumer or non-health professional</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>VM</patientinitial>
			<patientbirthdateformat>102</patientbirthdateformat>
			<patientbirthdate>19501113</patientbirthdate>
			<patientsex code="2">Female</patientsex>
			<reaction>
				<primarysourcereaction>Aching muscles</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Muscle pain</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Myalgia</reactionmeddrapt>
				<reactionoutcome code="3">not recovered/not resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Flu-like symptoms</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Flu-like symptoms</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Influenza like illness</reactionmeddrapt>
				<reactionoutcome code="3">not recovered/not resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Nausea</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Nausea</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Nausea</reactionmeddrapt>
				<reactionoutcome code="3">not recovered/not resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Diarrhea</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Diarrhea</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Diarrhoea</reactionmeddrapt>
				<reactionoutcome code="3">not recovered/not resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Vomiting</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Vomiting</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Vomiting</reactionmeddrapt>
				<reactionoutcome code="3">not recovered/not resolved</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>TASIGNA</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugbatchnumb>F0022B</drugbatchnumb>
				<drugauthorizationnumb>22-068</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>400</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugseparatedosagenumb>2</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>400 mg, BID</drugdosagetext>
				<drugdosageform normalized="capsule">Capsule</drugdosageform>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Chronic myeloid leukaemia</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2009-11-11</drugstartdate>
				<actiondrug code="4">Dose not changed</actiondrug>
				<drugadditional code="ExpDT=30-JUN-2014"/>
				<activesubstance>
					<activesubstancename>AMN107</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Diarrhoea</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Diarrhoea</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Influenza like illness</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Influenza like illness</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Myalgia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Myalgia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Nausea</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Nausea</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Vomiting</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Vomiting</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>HYDROCODONE W/APAP</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>HYDROCODONE, PARACETAMOL</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>LORAZEPAM</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>LORAZEPAM</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>CENESTIN</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>ESTROGENS CONJUGATED</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>PROPRANOLOL</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>PROPRANOLOL</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>PHENYTOIN</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>PHENYTOIN</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHEH2012US005409, is an <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">initial </Semaphore>spontaneous report received from consumer (patient) via <Semaphore x="2209948" class="Disease or Finding" value="Medical or Surgical Procedure Requiring Relocation of Lead" score="1.00" ID="C99983">specialty </Semaphore><Semaphore x="2394141" class="Occupation" value="Pharmacist" score="1.00" ID="C51840">pharmacy </Semaphore>(Walgreens) received on 08 Mar 2012, with a follow up report from consumer (patient's spouse) via <Semaphore x="2209948" class="Disease or Finding" value="Medical or Surgical Procedure Requiring Relocation of Lead" score="1.00" ID="C99983">specialty </Semaphore><Semaphore x="2394141" class="Occupation" value="Pharmacist" score="1.00" ID="C51840">pharmacy </Semaphore>(Walgreens) received on 05 Dec 2012. This report refers to 61-years old female patient. The patient's medical history was not reported. This poly medicated patient received <Semaphore x="1248114" class="Medicine" value="Tasigna" score="0.74" ID="282225">Tasigna </Semaphore>(<Semaphore x="928154" class="Medicine" value="nilotinib" score="0.49" ID="278855">nilotinib</Semaphore>) for <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>of <Semaphore x="1779493" class="Disease or Finding" value="Chronic Leukemia" score="1.00" ID="C3483">chronic <Semaphore x="3120003" class="MedDRA LLT" value="Myeloid leukaemia" score="1.00" ID="10028549">myeloid leukemia </Semaphore></Semaphore>(<Semaphore x="1780469" class="Disease or Finding" value="Chronic Myelogenous Leukemia, BCR-ABL1 Positive" score="1.00" ID="C3174">CML</Semaphore>) from 11 Nov 2009, at a dose of 400 mg, BID <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">orally</Semaphore>. On an unspecified date, the patient experienced <Semaphore x="2262749" class="Disease or Finding" value="Nausea" score="1.00" ID="C3258">nausea </Semaphore>(occasional), <Semaphore x="3037782" class="MedDRA LLT" value="Influenza like illness" score="1.00" ID="10022004"><Semaphore x="1412208" class="Disease or Finding" value="Ache" score="1.00" ID="C86024">aching </Semaphore><Semaphore x="2246514" class="AnatomicStructure" value="Muscle Tissue" score="1.00" ID="C12435">muscles </Semaphore>and <Semaphore x="3037909" class="MedDRA LLT" value="Influenza" score="1.00" ID="10022000"><Semaphore x="1940693" class="Disease or Finding" value="Flu-Like Symptoms" score="1.00" ID="C78302">flu like </Semaphore>
      <Semaphore x="1940693" class="Disease or Finding" value="Flu-Like Symptoms" score="1.00" ID="C78302">symptoms</Semaphore></Semaphore></Semaphore>
    . In 2009 (exact date unspecified), the patient experienced <Semaphore x="2693861" class="Disease or Finding" value="Vomiting" score="1.00" ID="C3442">vomiting </Semaphore>and <Semaphore x="1847734" class="Disease or Finding" value="Diarrhea" score="1.00" ID="C2987">diarrhea </Semaphore>occasionally. The <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>with <Semaphore x="1248114" class="Medicine" value="Tasigna" score="0.74" ID="282225">Tasigna </Semaphore>was ongoing as of an unknown date. The <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>of the events was reported as condition <Semaphore x="1409602" class="Procedure" value="About What Time is it" score="1.00" ID="C110931">unchanged </Semaphore>as of an unknown date. No further information was available.Follow up report from consumer (patient's spouse) via <Semaphore x="2209948" class="Disease or Finding" value="Medical or Surgical Procedure Requiring Relocation of Lead" score="1.00" ID="C99983">specialty </Semaphore><Semaphore x="2394141" class="Occupation" value="Pharmacist" score="1.00" ID="C51840">pharmacy </Semaphore>(Walgreens) received on 05 Dec 2012: Updated events (<Semaphore x="1847734" class="Disease or Finding" value="Diarrhea" score="1.00" ID="C2987">diarrhea </Semaphore>and <Semaphore x="2693861" class="Disease or Finding" value="Vomiting" score="1.00" ID="C3442">vomiting</Semaphore>) and their <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcomes</Semaphore>.</narrativeincludeclinical>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>